An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies

PHASE3CompletedINTERVENTIONAL
Enrollment

236

Participants

Timeline

Start Date

April 23, 2019

Primary Completion Date

March 25, 2022

Study Completion Date

March 30, 2022

Conditions
Huntington Disease
Interventions
DRUG

RO7234292 (RG6042)

Intrathecal injection

Trial Locations (38)

6020

Uniklinik fuer Neurologie, Medizinische Universitaet Innsbruck; Department fuer Neurologie, Innsbruck

10117

Charité - Universitätsmed. Berlin, Klinik für Psychiatrie und Psychotherapie; Abt. Neuropsychiatrie, Berlin

14226

Dent Neurological Institute, Amherst

15213

University of Pittsburgh, Pittsburgh

20007

Georgetown University; Research Division, Psychiatry, Washington D.C.

20133

Fondazione IRCCS Istituto Neurologico Carlo Besta; U.O.C. Genetica Medica-Neurogenetica, Milan

21287

John Hopkins University School of Medicine, Baltimore

28034

Hospital Ramon y Cajal; Servicio de Neurologia, Madrid

28040

Fundacion Jimenez Diaz; Servicio de Neurología, Madrid

33613

University of South Florida, Tampa

35294

Uab Medicine, Birmingham

37212

Vanderbilt University Medical Center, Nashville

41009

Hospital Universitario Virgen Macarena; Servicio de Neurologia, Seville

44791

St. Josef-Hospital, Neurologische Klinik der Ruhr-Uni; Huntington-Center NRW, Abt. Neurodegeneration, Bochum

60611

Northwestern University, Chicago

71013

IRCCS Casa Sollievo Della Sofferenza; Unità Ricerca e Cura Huntington e Malattie Rare, San Giovanni Rotondo (FG)

77030

The University of Texas Health Science Center at Houston; McGovern Medical School, Houston

80113

CenExel Rocky Mountain Clinical Research, LLC, Englewood

89081

Universitätsklinikum Ulm; Klinik für Neurologie, Ulm

91105

SC3 Research Group, Inc, Pasadena

92093

University of California San Diego, La Jolla

94304

Stanford Univ Medical Center, Palo Alto

10032-3725

Columbia University, New York

V6T 2B5

University of British Columbia Hospital; Division of Neurology, Vancouver

M3B 2S7

Centre for Movement Disorders, North YORK

K1Y 4E9

Ottawa Hospital Research Institute, Ottawa

H2X 0C2

Centre Hospitalier de l?Université de Montréal (CHUM), Montreal

9713 GZ

Universitair Medisch Centrum Groningen, Groningen

2333 ZA

LUMC, Leiden

06080

Hospital Universitario de Badajoz; Servicio de Neurología, Badajoz

08036

Hospital Clinic Servicio de Neurologia, Barcelona

08041

Hospital de la Santa Creu i Sant Pau; Servicio de Neurologia, Barcelona

09006

Hospital Universitario de Burgos. Servicio de Neurología, Burgos

B15 2TT

Birmingham and Solihull Mental Health Foundation Trust; Institute of Clinical Sciences, Birmingham

CB2 0SP

Cambridge Centre for Brain Repair; Department of Clinical Nuerosciences, Addenbrookes Hospital, Cambridge

CF14 4XW

University Hospital of Wales; Division of Psychological Medicine and Clinical Neurosciences, Cardiff

NW1 2PG

University College London Hospitals NHS Foundation Trust - University College Hospital, London

M13 9WL

Central Manchester University Hospitals NHS Foundation Trust; Manchester Centre for Genomic Medicine, Manchester

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03842969 - An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington's Disease Participants Who Participated in Prior Roche and Genentech Sponsored Studies | Biotech Hunter | Biotech Hunter